Apogee Therapeutics

APGE

Market cap $4.78B

Great Point Partners increased its APGE position by 70,000 shares in the fourth quarter; the estimated transaction value was $4.41 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $16.15 million, reflecting both share purchases and price movement.

SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026.

Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $122.20 million, including changes from both trading and price movements.

Affinity Asset Advisors bought 61,500 shares of Apogee Therapeutics in the fourth quarter; the estimated transaction value was $3.87 million (based on quarterly average prices). Meanwhile, the quarter-end position value rose by $46.59 million, reflecting both trade and stock price movement.

SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 2:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash position provides operational runway into 2028, supporting pivotal Phase II/III trials without near-term dilution risk. Zumilokibart's extended half-life and clean safety profile position APGE to challenge Dupixent, with physician surveys indicating strong preference for reduced dosing frequency.

The chief medical officer at Apogee Therapeutics sold 18,700 shares of the biotech for about $1.46 million. This sale represented 8.09% of Dambkowski's direct holdings, reducing his direct stake, as reported, from 231,223 to 212,523 shares.

10,900 shares directly sold for a total transaction value of $817,500 on Dec. 4, 2025. The transaction represented 3.87% of CMO Carl Dambkowski's direct holdings, reducing direct ownership from 282,008 to 271,108 shares.

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued development in asthma testing every 3- or 6-month dosing